Cadrenal Therapeutics, Inc.
Climate Impact & Sustainability Data (2023)
Reporting Period: 2023
Environmental Metrics
Climate Goals & Targets
Medium-term Goals:
- Expand the label for tecarfarin through a supplemental NDA.
- Explore additional indications for tecarfarin.
Short-term Goals:
- Complete clinical development and seek FDA approval for tecarfarin.
Environmental Challenges
- Limited operating history and history of losses.
- Need for additional capital to fund operations and clinical trials.
- Dependence on the success of tecarfarin.
- Competition from major pharmaceutical companies.
- Risks related to product development, regulatory approval, manufacturing, and commercialization.
- Risks related to intellectual property.
- Risks related to ownership of common stock.
- General company-related risks including attracting and retaining personnel, managing growth, product liability, computer system failures, cybersecurity risks, and acquisitions.
- Risks related to global health crises.
- Compliance with regulations regarding animal treatment.
Mitigation Strategies
- Securing orphan drug and Fast Track designations for tecarfarin.
- Planning a pivotal Phase 3 clinical trial.
- Exploring strategic partnerships and licensing agreements.
- Developing a commercial infrastructure.
- Maintaining a cyber risk management protocol.
- Carrying product liability insurance.